XML 88 R65.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Summary of Financial Data for Development of Pharmaceutical Products Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 18, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Segment Reporting Information [Line Items]        
Revenues   $ 0 $ 65,297  
Impairment of long-lived assets $ 10,400 0 10,899  
Gain on disposition of a non-financial asset   (500) 0  
Net (loss) income   (15,945) 17,778 $ (32,000)
Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Revenues   0 65,297  
Employee expenses   9,293 13,207  
Other segment expenses [1]   2,647 9,946  
Professional fees   2,754 4,092  
Legal fees   1,723 3,397  
Impairment of long-lived assets   0 10,899  
Fees paid on behalf of a related party   0 1,118  
Gain on disposition of a non-financial asset   (500) 0  
Interest and dividend income   (1,026) (3,277)  
Total operating and other (income) expense   15,945 47,519  
Net (loss) income   (15,945) 17,778  
Operating Segments [Member] | voruciclib        
Segment Reporting Information [Line Items]        
Other segment expenses   801 3,413  
Operating Segments [Member] | ME-344        
Segment Reporting Information [Line Items]        
Other segment expenses   $ 253 $ 4,724  
[1]

(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.